Inactive Instrument

Grindeks

GRD1R

LV0000100659

As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019

February 28, 2020 at 10:04 am EST

AS Grindeks announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was EUR 141.417 million compared to EUR 145.477 million a year ago. Net income was EUR 12.886 million compared to net loss of EUR 9.732 million a year ago. Basic earnings per share was EUR 1.34 compared to basic loss per share of EUR 1.02 a year ago.

Latest news about Grindeks

Grindeks Opens New Subsidiaries Worldwide	Apr. 03	CI
JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	21-02-24	CI
SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	21-01-21	CI
SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	20-12-21	CI
Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-26	CI
Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-27	CI
Akciju sabiedriba Grindeks Approves to Pay Dividend, Payable on September 17, 2020	20-08-18	CI
Akciju sabiedriba Grindeks Proposes to Pay Dividend, Payable on September 17, 2020 and November 17, 2020, Respectively	20-08-04	CI
Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	20-03-05	CI
As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-28	CI
JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	20-02-04	CI
JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	20-01-22	CI
JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	19-12-19	CI
As Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-28	CI
As Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-29	CI
Grindeks Announces Dividend, Payable August 01, 2019	19-07-03	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans completed the acquisition of 20.17% stake AS Grindeks for €24.3 million.	19-06-27	CI
AS Grindeks Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-30	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans have bid to acquire remaining 27.36% stake in AS Grindeks for €33 million.	19-05-23	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans acquired an additional 22.66% stake in AS Grindeks from AmberStone Group, AS.	19-05-22	CI
Grindeks Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018	19-04-30	CI
Grindeks Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2018; Provides Group Earnings Guidance for the Full Year of Fiscal 2019	19-02-28	CI
AS Grindeks Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-29	CI
Grindeks Decides on Distribution of the Profit for the Year 2017, Payment Date of September 12, 2018	18-09-06	CI
JSC Grindeks Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2018	18-08-31	CI

Chart Grindeks

Duration

Period

More charts

Company Profile

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.27%	43.75B
OTSUKA HOLDINGS CO., LTD.	+24.79%	22.06B
SANDOZ GROUP AG	+15.11%	14.46B
CIPLA LIMITED	+12.33%	13.62B
ZYDUS LIFESCIENCES LIMITED	+38.36%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-7.93%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+10.21%	5.32B

Generic Pharmaceuticals